Presentations

Virtual Investor Event

To discuss the current spinal cord injury treatment landscape and
NervGen’s Phase 1b/2a trial evaluating NVG-291 in spinal cord injury

April 9, 2025 | 10:00am EDT
Click here to register and attend the event

Oppenheimer 35^th Annual Healthcare Life Sciences Conference

February 11, 2025 | 8:40am EST
Click here to listen to the fireside chat

Virtual Life Sciences Investor Forum

Hosted by OTC Markets Group and VirtualInvestorConferences.com
March 13, 2025 | 12:00pm EDT
Click here to listen to the presentation

Webinar Panel Discussion:

Clinical Research Advancements in Spinal Cord Injury (SCI)

September 5, 2024 | 5:00pm EDT
Click here to listen to the webinar

Current Corporate Presentation

Click here to view NervGen’s corporate presentation

NVG-291 and Stroke

Click here to view the presentation on NVG-291-R and the results seen in stroke in Cell Reports.

NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.

Contact

112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4

Phone: (778) 731-1711
Email: info@nervgen.com

Subscribe for Updates